Adoptive immunotherapy for advanced cancer patients using in vitro activated cytotoxic T lymphocytes

Journal of Surgical Oncology

Volumn 72, Issue 4, 1999, Pages 211-217

  Soda, Hiroaki ^a,c   Koda, Keiji ^b   Yasutomi, Jun ^a   Oda, Kenji ^a   Takiguchi, Nobuhiro ^a   Saito, Norio ^a   Nakajima, Nobuyuki ^a  

^a CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c CHIBA CANCER CENTER   (Japan)

Author keywords

Adoptive immunotherapy; Clinical trial; Cytotoxic T lymphocytes; Mixed lymphocytes and tumor cell culture

Indexed keywords

B7 ANTIGEN; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; TUMOR MARKER;

ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; CELL POPULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

AGED; ANTIGENS, CD14; BONE NEOPLASMS; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033407119     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199912)72:4<211::AID-JSO6>3.0.CO;2-A     Document Type: Article

References (21)

1. Mitchison NA: Studies on the immunological response to foreign tumor transplants in the mouse. J Exp Med 1955;102:157-177.
2. Yonemoto RH, Terasaki PI: Cancer immunotherapy with HLA-compatible thoracic duct lymphocyte transplantation. A preliminary report. Cancer 1972;30:1438-1443.
3. Moore GE, Gerner RE: Cancer immunity - hypothesis and clinical trial of lymphocytotherapy for malignant diseases. Ann Surg 1970;174:733-739.
4. Feneley RC, Eckert H, Riddell AG, et al.: The treatment of advanced bladder cancer with sensitized pig lymphocytes. Br J Surg 1974;61:825-827.
5. Rosenberg SA, Lotze MT, Muul LM, et al.: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-1492.
6. Ettinghausen SE, Puri RK, Rosenberg SA: Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst 1988;80:177-188.
7. Itoh K, Platsoucas CD, Balch CM: Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 1988; 168:1419-1441.
8. Baxevanis CN, Dedoussis GV, Papadopoulos NG, et al.: Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 1994;74:1275-1282.
9. Knuth A, Wolfel T, Meyer zum Buschenfelde KH: T cell responses to human malignant tumors. Cancer Surv 1992;13:39-52.
10. Wolfel T, Herr W, Coulie P, et al.: Lysis of human pancreatic adenocarcinoma cells by autologous HLA-class I-restricted cytolytic T-lymphocyte (CTL) clones. Int J Cancer 1993;54:636-644.
11. Hoshino T, Seki N, Kikuchi M, et al.: HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer. Int J Cancer 1997;70:631-638.
12. Gohara R, Nakao M, Ogata Y, et al.: Histocompatibility leukocyte antigen-A2402-restricted cytotoxic T lymphocytes recognizing adenocarcinoma in tumor-infiltrating lymphocytes of patients with colon cancer. Jpn J Cancer Res 1997;88:198-204.
13. Saitoh S, Kurisaka M, Mori K, et al.: Induction of specific cytotoxic T lymphocytes against autologous brain tumor by crossreactive allo-tumor cell stimulation. Jpn J Cancer Res 1997;88:289-295.
14. Chikamatsu K, Eura M, Matsuoka H, et al.: The role of major histocompatibility complex expression on head and neck cancer cells in the induction of autologous cytotoxic T lymphocytes. Cancer Immunol Immunother 1994;38:358-364.
15. +) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumor cells. Clin Exp Immunol 1995;101:362-368.
16. Vanky F, Hising C, Sjowall K, et al.: Interferon-gamma and tumor necrosis factor-alpha treatment of ex vivo human carcinoma cells potentiates their interaction with allogeneic lymphocytes. J Interferon Cytokine Res 1996;16:201-207.
17. Li J, Yang Y, Inoue H, et al.: The expression of costimulatory molecules CD80 and CD86 in human carcinoma cell lines: Its regulation by interferon gamma and interleukin-10. Cancer Immunol Immunother 1996;43:213-219.
18. + T cell activity. J Immunol 1992;148:648-655.
19. + T cell responsiveness, suppressed in the tumor-bearing state, by release from tumor burden. J Cancer Res Clin Oncol 1994;120:279-285.
20. Tada T, Ohzeki S, Utsumi K, et al.: Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991;146:1077-1082.
21. Fujimoto S, Araki K, Hamasato S, et al.: Development of specific immunotherapy for cancer. (in Japanese) Hum Cell 1992;5:247-255.